Clinical trials: Cancer of Brain
Non-Small Cell Lung Cancer
Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases
This is a multicenter, non-interventional, observational real-world study to evaluate the efficacy and safety of Taletrectinib in ROS1-positive non-small cell lung cancer (NSCLC) with brain metastases.
- Trial name
- NCT07008287
- Testing
- Taletrectinib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Early Alzheimer's Disease
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
The primary objective of the study is to evaluate the effects of hepatic impairment on the pharmacokinetics (PK) of E2609 after a single dose administration.
- Trial name
- NCT02859207
- Testing
- E2609
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Brain and Central Nervous System Tumors, Lymphoma
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating children who have advanced solid…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00004212
- Testing
- filgrastim, exatecan mesylate
- Where
- 4 sites in United States
- Sponsor
- Daiichi Sankyo
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Malignant Glioma, Anaplastic Astrocytoma
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
The purpose of the study is to confirm the safety of the selected dose and potential toxicity of oncolytic poliovirus (PV) immunotherapy with PVSRIPO for pediatric patients with recurrent WHO grade III or IV malignant glioma, but…
- Conditions
- Malignant Glioma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT03043391
- Testing
- Polio/Rhinovirus Recombinant (PVSRIPO)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Istari Oncology, Inc.
Primary Malignant Brain Tumor
A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors
Overall Design: This is a phase I, open-label, multicenter clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer efficacy of ABM-1310 in patients with BRAF V600-mutant relapsed and…
- Trial name
- NCT05892653
- Testing
- ABM-1310
- Where
- 4 sites in China
- Volunteers
- 15 people
- Sponsor
- ABM Therapeutics Shanghai Company Limited
High Grade Glioma, Glioblastoma Multiforme
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
This is a study of DSP-0390 in patients with recurrent high grade glioma.
- Trial name
- NCT05023551
- Testing
- DSP-0390
- Where
- 9 sites in United States, Japan
- Volunteers
- 39 people
- Sponsor
- Sumitomo Pharma America, Inc.
1-5 Brain Metastases From Non-Small Cell Lung Cancer
Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)
The study is a prospective, randomly controlled phase II trial, designed to test the efficacy, safety and neurocognitive outcomes of a medical device, the NovoTTF-100A, in the treatment of NSCLC patients with controlled systemic…
- Trial name
- NCT01755624
- Testing
- NovoTTF-100A device, Best Standard of Care
- Where
- 7 sites in Czechia, France and 3 more
- Volunteers
- 18 people
- Sponsor
- NovoCure Ltd.
Malignant Brain Tumors
Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation
This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK of HSK42360 when given orally in pediatric patients with active BRAF V600 mutation recurrent malignant brain tumors.
- Trial name
- NCT07158710
- Testing
- HSK42360
- Where
- 6 sites in China
- Volunteers
- 159 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Glioblastoma, Small Cell Glioblastoma
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
The purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as CDX-110) to the commonly used drug bevacizumab can improve progression free survival (slowing the growth…
- Conditions
- Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
- Trial name
- ReACT (NCT01498328)
- Testing
- Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH
- Where
- 45 sites in United States
- Volunteers
- 127 people
- Sponsor
- Celldex Therapeutics
Brain Tumor
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric…
- Trial name
- NCT05630209
- Testing
- Exablate, Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- InSightec
Malignant Glioma
G207 Followed by Radiation Therapy in Malignant Glioma
This is an open-label, single site study to evaluate the safety and tolerability of intratumoral administration of G207 followed by treatment with radiation therapy in patients with recurrent/progressive malignant glioma.
- Trial name
- NCT00157703
- Testing
- G207
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- MediGene
Diffuse Midline Glioma (DMG), Diffuse Intrinsic Pontine Glioma (DIPG)
Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response
Open-label, dose-escalating, Phase 1/2a trial of Large Surface Area Microparticle (LSAM)-Cisplatin to treat participants with diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG), via stereotactic…
- Conditions
- Diffuse Midline Glioma (DMG), Diffuse Intrinsic Pontine Glioma (DIPG), Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
- Trial name
- TIGER-1 (NCT07767110)
- Testing
- LSAM-Cisplatin
- Volunteers
- 20 people
- Sponsor
- NanOlogy, LLC
Breast Cancer, Brain Metastases
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in breast cancer patients with recurrent brain metastases.
- Trial name
- NCT02048059
- Testing
- ANG1005
- Where
- 19 sites in United States
- Volunteers
- 72 people
- Sponsor
- Angiochem Inc
Glioma
Study of GC101 TIL in Brain Glioma (Soochow2)
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant glioma . Autologous TILs are expanded from tumor resections and infused i.v.
- Trial name
- NCT04943913
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Juncell Therapeutics
Glioblastoma
Discerning Pseudoprogression vs True Tumor Growth in GBMs
One-third of all primary brain tumors are astrocytomas, the most common type of glioma. Grade 4 astrocytomas, more commonly known as glioblastomas (GBMs), represent about 50% of all gliomas (annual incidence of over 3 per…
- Trial name
- NCT02905643
- Testing
- Study subjects
- Volunteers
- 1 people
- Sponsor
- Ascension Health
Breast Cancer, Brain Metastases
Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases
The purpose of this study is to evaluate the safety of BBB disruption using the ExAblate 4000-system Type 2 in patients with Her-2 positive breast cancer metastases in the brain.
- Trial name
- BBBD (NCT03714243)
- Testing
- ExAblate BBBD
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- InSightec
Brain Metastases
Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
In this dose-escalation study, the safety and tolerability of escalating dose levels of RRx-001 administered intravenously twice a week in subjects with brain metastases receiving whole brain radiation therapy (WBRT) will be…
- Trial name
- BRAINSTORM (NCT02215512)
- Testing
- RRx-001 + WBRT
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- EpicentRx, Inc.
Brain Tumour, High Grade Glioma
SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue
The objective of this clinical investigation is to assess the safety and performance of the SonoClear Acoustic Coupling Fluid (ACF).
- Conditions
- Brain Tumour, High Grade Glioma, Low-grade Glioma, Glioblastoma
- Trial name
- NCT04734444
- Testing
- SonoClear ACF
- Where
- 4 sites in Germany, Italy and 1 more
- Volunteers
- 45 people
- Sponsor
- SonoClear AS
Alzheimer Disease, Dementia
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
The goal of this Phase 2 Open Label study is to evaluate long-term safety, tolerability, and efficacy of XPro1595 on measures of cognition, function and brain quality in individuals with Alzheimer's Disease.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05522387
- Testing
- XPro1595
- Where
- 4 sites in Australia
- Volunteers
- 11 people
- Sponsor
- Inmune Bio, Inc.